These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 23274955)

  • 1. Agalsidase benefits renal histology in young patients with Fabry disease.
    Tøndel C; Bostad L; Larsen KK; Hirth A; Vikse BE; Houge G; Svarstad E
    J Am Soc Nephrol; 2013 Jan; 24(1):137-48. PubMed ID: 23274955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
    Skrunes R; Tøndel C; Leh S; Larsen KK; Houge G; Davidsen ES; Hollak C; van Kuilenburg ABP; Vaz FM; Svarstad E
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1470-1479. PubMed ID: 28625968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients.
    Skrunes R; Svarstad E; Kampevold Larsen K; Leh S; Tøndel C
    Nephrol Dial Transplant; 2017 May; 32(5):807-813. PubMed ID: 27190352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
    Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
    Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.
    Lubanda JC; Anijalg E; Bzdúch V; Thurberg BL; Bénichou B; Tylki-Szymanska A
    Genet Med; 2009 Apr; 11(4):256-64. PubMed ID: 19265719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of switching from agalsidase-α to agalsidase-β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report.
    Shima H; Tsukimura T; Shiga T; Togawa T; Sakuraba H; Doi T; Ikeda Y; Okamoto T; Yoshikawa Y; Kimura T; Iwase T; Inoue T; Tashiro M; Okada K; Minakuchi J
    CEN Case Rep; 2024 Aug; 13(4):290-296. PubMed ID: 38135868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.
    Schiffmann R; Ries M; Blankenship D; Nicholls K; Mehta A; Clarke JT; Steiner RD; Beck M; Barshop BA; Rhead W; West M; Martin R; Amato D; Nair N; Huertas P
    Genet Med; 2013 Dec; 15(12):983-9. PubMed ID: 23680766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
    Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
    Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy for Anderson-Fabry disease.
    El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America.
    Ripeau D; Amartino H; Cedrolla M; Urtiaga L; Urdaneta B; Cano M; Valdez R; Antongiovanni N; Masllorens F
    Medicina (B Aires); 2017; 77(3):173-179. PubMed ID: 28643672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
    Sasa H; Nagao M; Kino K
    Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agalsidase alfa: a review of its use in the management of Fabry disease.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
    Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
    J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.
    Weidemann F; Krämer J; Duning T; Lenders M; Canaan-Kühl S; Krebs A; Guerrero González H; Sommer C; Üçeyler N; Niemann M; Störk S; Schelleckes M; Reiermann S; Stypmann J; Brand SM; Wanner C; Brand E
    J Am Soc Nephrol; 2014 Apr; 25(4):837-49. PubMed ID: 24556354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
    Wallace EL; Goker-Alpan O; Wilcox WR; Holida M; Bernat J; Longo N; Linhart A; Hughes DA; Hopkin RJ; Tøndel C; Langeveld M; Giraldo P; Pisani A; Germain DP; Mehta A; Deegan PB; Molnar MJ; Ortiz D; Jovanovic A; Muriello M; Barshop BA; Kimonis V; Vujkovac B; Nowak A; Geberhiwot T; Kantola I; Knoll J; Waldek S; Nedd K; Karaa A; Brill-Almon E; Alon S; Chertkoff R; Rocco R; Sakov A; Warnock DG
    J Med Genet; 2024 May; 61(6):520-530. PubMed ID: 37940383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
    Lenders M; Canaan-Kühl S; Krämer J; Duning T; Reiermann S; Sommer C; Stypmann J; Blaschke D; Üçeyler N; Hense HW; Brand SM; Wanner C; Weidemann F; Brand E
    J Am Soc Nephrol; 2016 Mar; 27(3):952-62. PubMed ID: 26185201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
    Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
    Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
    Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
    J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes in elderly patients receiving agalsidase alfa treatment in the Fabry Outcome Survey.
    Nowak A; Botha J; Anagnostopoulou C; Hughes DA
    Mol Genet Metab; 2024; 143(1-2):108561. PubMed ID: 39159540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.